Is Biogen, Inc. overvalued or undervalued?

As of 17 October 2025, Biogen, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued, with a P/E ratio of 13, an EV to EBITDA of 9.17, and a PEG ratio of 0.61, indicating a potentially favorable investment opportunity relative to its earnings growth. In comparison, its peer, which has a P/E of approximately 13.57 and an EV to EBITDA of 8.89, suggests that Biogen may be trading at a discount to its competitors.
Despite this attractive valuation, Biogen's stock has significantly underperformed against the S&P 500, with a one-year return of -24.56% compared to the index's 14.08%. This stark contrast in performance may reflect market concerns that could affect future growth prospects.